📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol. (2022)

First Author: Krolewiecki A

Attributed to: The generation and maintenance of genetic novelty in helminth populations funded by UKRI FLF

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.12688/gatesopenres.13615.1

PubMed Identifier: 36540062

Publication URI: http://europepmc.org/abstract/MED/36540062

Type: Journal Article/Review

Volume: 6

Parent Publication: Gates open research

ISSN: 2572-4754